Etiology of Lymphopenia in Covid19 Infection

Learn more about:
Related Clinical Trial
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort) Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19 Study of Lymphopenia as a Specific Biomarker or Prognostic Risk Factor for Disease Severity in Elderly Patients With COVID-19 InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ) InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-O ) InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort Etiology of Lymphopenia in Covid19 Infection Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant Pyridostigmine as Immunomodulator in People Living With HIV Regional Differences in Human Immunodeficiency Virus (HIV) Testing Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort Safety Study of IL-7 in HIV-infected Patients (Inspire) Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas Lymphocyte Count as a Sign of Immunoparalysis and Its Correlation With Nutritional Status in Septic Pediatric Patients Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Brief Title

Etiology of Lymphopenia in Covid19 Infection

Official Title

Study of the Etiology of Lymphopenia in Covid19 Viral Infection

Brief Summary

      Study of the cause of lymphopenia in Covid19 viral infection will be done in 3 cohorts. First
      cohort will be patients asymptomatic or with mild symptoms. Second cohort will be patients
      with severe illness and admitted to ICU. Third cohort will be patients critically ill and on
      artificial ventilation.
    

Detailed Description

      Each cohort will include 30 patients. Complete blood count in all patients will be done daily
      in all patients. Bone marrow aspiration cytology will be done in some selected patients
      especially those with lymphopenia less than 1000 per cubic mm.

      Correlation of the degree of lymphopenia with the status of the patients will be done. Also
      correlation will be done about the relation of recovery of lymphopenia and status of the
      patients.
    


Study Type

Observational


Primary Outcome

Death or recovery


Condition

Lymphopenia

Intervention

Complete blood picture, bone marrow aspiration cytology

Study Arms / Comparison Groups

 Asymptomatic or mild symptoms patients patients
Description:  Patients with no or mild symptoms and need no respiratory support.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Diagnostic Test

Estimated Enrollment

90

Start Date

June 2020

Completion Date

December 2021

Primary Completion Date

June 2021

Eligibility Criteria

        Inclusion Criteria:

          -  Any patient admitted with the diagnosis of Covid19 viral infection

        Exclusion Criteria:

          -  Any patient who died within one day of admission
      

Gender

All

Ages

N/A - N/A


Contacts

, , 



Administrative Informations


NCT ID

NCT04404608

Organization ID

201920008.2


Responsible Party

Sponsor-Investigator

Study Sponsor

Dr Medhat Khafagy


Study Sponsor

, , 


Verification Date

May 2020